Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Richard A Larson

Showing results (261-270 of 383) with videos related to

Pageof 39
Sort By:
Blood|August 11, 2011
Low expression of MN1 associates with better treatment response in older patients with de novo cytogenetically normal acute myeloid leukemiaSebastian Schwind, Guido Marcucci, Jessica Kohlschmidt, et al.
Blood|April 2, 2008
High BAALC expression associates with other molecular prognostic markers, poor outcome, and a distinct gene-expression signature in cytogenetically normal patients younger than 60 years with acute myeloid leukemia: a Cancer and Leukemia Group B (CALGB) studyChristian Langer, Michael D Radmacher, Amy S Ruppert, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 24, 2008
Prognostic significance of, and gene and microRNA expression signatures associated with, CEBPA mutations in cytogenetically normal acute myeloid leukemia with high-risk molecular features: a Cancer and Leukemia Group B StudyGuido Marcucci, Kati Maharry, Michael D Radmacher, et al.
Blood|August 22, 2008
An 86-probe-set gene-expression signature predicts survival in cytogenetically normal acute myeloid leukemiaKlaus H Metzeler, Manuela Hummel, Clara D Bloomfield, et al.
Blood Advances|February 20, 2020
A phase 1 study of azacitidine with high-dose cytarabine and mitoxantrone in high-risk acute myeloid leukemiaKirk E Cahill, Yasmin H Karimi, Theodore G Karrison, et al.
Blood Advances|November 15, 2019
Results from a multidisciplinary clinic guided by geriatric assessment before stem cell transplantation in older adultsBenjamin A Derman, Keriann Kordas, Jean Ridgeway, et al.
Blood|November 3, 2009
Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNetHartmut Döhner, Elihu H Estey, Sergio Amadori, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 13, 2005
Phase I study of oblimersen sodium, an antisense to Bcl-2, in untreated older patients with acute myeloid leukemia: pharmacokinetics, pharmacodynamics, and clinical activityGuido Marcucci, Wendy Stock, Guowei Dai, et al.
Journal of the National Cancer Institute|September 7, 2021
Patient-Reported Functional Outcomes in Patients With Chronic Myeloid Leukemia After Stopping Tyrosine Kinase InhibitorsKelly L Schoenbeck, Ehab Atallah, Li Lin, et al.
Cancer|August 24, 2005
Final report of the efficacy and safety of gemtuzumab ozogamicin (Mylotarg) in patients with CD33-positive acute myeloid leukemia in first recurrenceRichard A Larson, Eric L Sievers, Edward A Stadtmauer, et al.
Pageof 39

Showing results (261-270 of 383) with videos related to

Sort By:
Pageof 39
Blood|August 11, 2011
Low expression of MN1 associates with better treatment response in older patients with de novo cytogenetically normal acute myeloid leukemiaSebastian Schwind, Guido Marcucci, Jessica Kohlschmidt, et al.
Blood|April 2, 2008
High BAALC expression associates with other molecular prognostic markers, poor outcome, and a distinct gene-expression signature in cytogenetically normal patients younger than 60 years with acute myeloid leukemia: a Cancer and Leukemia Group B (CALGB) studyChristian Langer, Michael D Radmacher, Amy S Ruppert, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 24, 2008
Prognostic significance of, and gene and microRNA expression signatures associated with, CEBPA mutations in cytogenetically normal acute myeloid leukemia with high-risk molecular features: a Cancer and Leukemia Group B StudyGuido Marcucci, Kati Maharry, Michael D Radmacher, et al.
Blood|August 22, 2008
An 86-probe-set gene-expression signature predicts survival in cytogenetically normal acute myeloid leukemiaKlaus H Metzeler, Manuela Hummel, Clara D Bloomfield, et al.
Blood Advances|February 20, 2020
A phase 1 study of azacitidine with high-dose cytarabine and mitoxantrone in high-risk acute myeloid leukemiaKirk E Cahill, Yasmin H Karimi, Theodore G Karrison, et al.
Blood Advances|November 15, 2019
Results from a multidisciplinary clinic guided by geriatric assessment before stem cell transplantation in older adultsBenjamin A Derman, Keriann Kordas, Jean Ridgeway, et al.
Blood|November 3, 2009
Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNetHartmut Döhner, Elihu H Estey, Sergio Amadori, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 13, 2005
Phase I study of oblimersen sodium, an antisense to Bcl-2, in untreated older patients with acute myeloid leukemia: pharmacokinetics, pharmacodynamics, and clinical activityGuido Marcucci, Wendy Stock, Guowei Dai, et al.
Journal of the National Cancer Institute|September 7, 2021
Patient-Reported Functional Outcomes in Patients With Chronic Myeloid Leukemia After Stopping Tyrosine Kinase InhibitorsKelly L Schoenbeck, Ehab Atallah, Li Lin, et al.
Cancer|August 24, 2005
Final report of the efficacy and safety of gemtuzumab ozogamicin (Mylotarg) in patients with CD33-positive acute myeloid leukemia in first recurrenceRichard A Larson, Eric L Sievers, Edward A Stadtmauer, et al.
Pageof 39